RaysightMed secures nearly $15M Series D to advance precision cardiac diagnosis
What's the deal? RaysightMed, a Guangzhou-based medtech company specialising in AI-driven cardiac diagnosis and treatment, has closed a nearly RMB 100 million (~$15M) Series D round. The financing was led by Guangzhou Biopharma and Health Industry Investment Co., Ltd., with follow-on from Guangzhou Yuefu Fund ManagementDealroom has a profile for this one. Try Dealroom → Co., Ltd. — both state-owned capital platforms operating at the municipal and district levels in Guangzhou.
The funds will go toward pipeline development, overseas market expansion, and the company's work on an AI-driven vascular interventional surgical robot system.
Why now? RaysightMed has built a product portfolio spanning preoperative diagnosis, intraoperative assessment, and postoperative management for cardiovascular disease. Its flagship product, AngioQFA, provides one-stop assessment of coronary functional parameters and has gained traction with clinical experts in China since launch. The company has also struck a global distribution partnership with BluesailDealroom has a profile for this one. Try Dealroom →.
A second core product, RuiXin-FFR, offers non-invasive coronary functional assessment and is being rolled out in partnership with Xunfei Healthcare and IMLINCS. The company is also developing intracardiac echocardiography (ICE) technology for precision intracavitary applications.
What could go wrong? The round was backed entirely by state-owned funds — a pattern that can signal strong government support but may also raise questions about whether private investors see the same opportunity. Expanding internationally from a China-first base adds regulatory and commercial complexity, particularly in markets like the US and Europe where AI-enabled medical devices face rigorous approval processes.
Competition in AI-powered cardiac diagnostics is also intensifying, with well-funded players like HeartFlow already established in Western markets.
The signal: State capital is increasingly flowing into China's medtech sector, particularly where AI intersects with clinical hardware like surgical robots and diagnostic imaging. RaysightMed's integrated approach — combining AI, hemodynamics simulation, and robotics into a single platform — reflects a broader industry push toward end-to-end precision medicine solutions rather than point tools.
Read more: GS Medtech
